Skip to content
How It Works
Explore
Resources Ask a Question
Who It's For
Patients Caregivers Providers
Log In Ask a Question
PubMed This is a summary of 20 peer-reviewed journal articles Updated
Infectious Disease

Your Treatment Roadmap: IV and Oral Phases

At a Glance

Melioidosis requires a strict, two-phase antibiotic treatment plan to fully clear the resilient bacteria. This involves an intensive 10 to 14-day IV phase in the hospital, followed by a mandatory 12-week oral eradication phase at home to prevent a life-threatening relapse.

Because the bacteria that cause melioidosis (Burkholderia pseudomallei) are exceptionally resilient and can hide inside your cells, the treatment is much longer and more intensive than for a typical infection [1]. To ensure the bacteria are completely cleared and do not return, medical guidelines require a strict two-phase treatment plan [2][3].

Phase 1: The Intensive Phase (IV)

The goal of the first phase is to stop the bacteria from spreading and to treat the most severe symptoms. This phase almost always takes place in a hospital [4].

  • Medications: Doctors typically use Ceftazidime or Meropenem [4]. Meropenem is often preferred for very severe cases, such as those involving the blood or the brain [5][6].
  • Duration: This phase usually lasts a minimum of 10 to 14 days [4].
  • Extensions: If the infection is in the brain (neuromelioidosis), bones (osteomyelitis), or involves large abscesses in the liver or spleen, your doctor may extend the IV phase to 4 weeks or longer [7][8].

Phase 2: The Eradication Phase (Oral)

Once you are stable and the initial infection is under control, you will move to the oral phase. This is the most critical part of preventing the disease from coming back [2][9].

  • Medication: The standard “gold-label” treatment is Trimethoprim-sulfamethoxazole (TMP-SMX), also known by brand names like Bactrim or Septra [9]. If you have a sulfa allergy or are pregnant, your doctor will likely prescribe Amoxicillin-clavulanate (co-amoxiclav) as an effective, standard alternative [10][11].
  • Duration: You must take this medication for at least 12 weeks (3 months) [2]. In complex cases, this may be extended to 6 months [2][12].
  • Why so long? Unlike common bacteria, B. pseudomallei can stay dormant (sleeping) in your body for long periods. Stopping the medication early gives these “sleeper” bacteria a chance to wake up and cause a life-threatening relapse [1][2].

Monitoring for Side Effects

While oral antibiotics for melioidosis are highly effective, they are strong medications that require careful monitoring. If you are on TMP-SMX, watch for:

System Potential Side Effects to Watch For
Skin New rashes, hives, or peeling skin (Contact your doctor immediately for any rash) [11]. Sun Sensitivity: TMP-SMX makes your skin extremely sensitive to the sun. Wear high-SPF sunscreen and protective clothing to avoid severe sunburns [11].
Kidneys Changes in how much you urinate. You must drink plenty of water while on TMP-SMX to flush your kidneys and prevent strain [13][14].
Blood Unusual bruising, pale skin, or extreme fatigue (signs of low blood counts) [13][15].
Liver Yellowing of the eyes or skin (jaundice) or dark-colored urine [16].
Electrolytes Confusion or muscle weakness caused by high potassium or low sodium levels [13].

Daily Medication Safety

Because maintaining a steady level of antibiotics is crucial, set alarms to take your pills at the same time every day [2].

  • Missed Doses: If you accidentally miss a dose, take it as soon as you remember, unless it is almost time for your next dose. Do not “double up” to make up for a missed pill. If you are unsure, call your pharmacist for guidance [2].

Treatment Strategy by Severity

The path your treatment takes depends on how the infection has manifested in your body:

  1. Localized (Skin/Sores Only): Standard 10–14 days of IV therapy followed by 12 weeks of oral therapy [4][2].
  2. Deep-Seated (Lungs, Spleen, Liver, Prostate): Minimum 14 days of IV therapy, but often longer if abscesses haven’t shrunk on follow-up scans [7][17].
  3. Severe/Disseminated (Bloodstream or Brain): Aggressive IV therapy with Meropenem for 4+ weeks, followed by a very strict, potentially longer oral eradication phase [18][19].

Note: Your doctor may prescribe folic acid to take alongside your oral antibiotics to help protect your blood cells from certain side effects [20][2].

Return to the Home Page

Common questions in this guide

Why do I need to take oral antibiotics for melioidosis for at least 12 weeks?
The bacteria that cause melioidosis can stay dormant inside your cells. The long oral eradication phase is absolutely critical to completely clear these sleeping bacteria and prevent the disease from coming back.
What are the side effects of TMP-SMX (Bactrim) during melioidosis treatment?
Common side effects include severe sun sensitivity, skin rashes, and changes in kidney, liver, or blood function. You must drink plenty of water, wear high-SPF sunscreen, and contact your doctor immediately if you develop a new rash.
How do doctors determine the length of my intensive IV phase?
The length of your IV phase depends on the location and severity of the infection. While a standard skin infection may only need 10 to 14 days, infections in the brain, bones, or large organs may require 4 weeks or longer of IV antibiotics.
What happens if I am allergic to the oral eradication antibiotics?
If you have a known sulfa allergy or develop a severe rash or reaction to TMP-SMX, your doctor will likely prescribe amoxicillin-clavulanate (co-amoxiclav) as a standard, effective alternative for your oral phase.
What should I do if I accidentally miss a dose of my oral antibiotics?
If you miss a dose, take it as soon as you remember unless it is almost time for your next one. Never double up on pills to make up for a missed dose. Maintaining a strict, daily schedule is vital for the treatment to work.

Questions to Ask Your Doctor

Curated prompts to bring to your next appointment.

  1. 1.How did you determine the length of my intensive IV phase—is it based on the location of my infection (like lungs or bones)?
  2. 2.Is my oral dose calculated based on my weight to ensure it's effective but not overly toxic?
  3. 3.What blood tests will we use to monitor my kidney and liver function while I am on the 12-week oral phase?
  4. 4.If I develop a rash or severe nausea from the antibiotics, what is our 'Plan B' for eradication therapy?
  5. 5.Do I need to take folic acid supplements to help prevent blood-related side effects?

Questions For You

Tap a prompt to share your answer — we'll use it plus this page's context to start a tailored conversation.

References

References (20)
  1. 1

    Loss of Methyltransferase Function and Increased Efflux Activity Leads to Doxycycline Resistance in Burkholderia pseudomallei.

    Webb JR, Price EP, Currie BJ, Sarovich DS

    Antimicrobial agents and chemotherapy 2017; (61(6)) doi:10.1128/AAC.00268-17.

    PMID: 28348161
  2. 2

    Oral eradication therapy for melioidosis: Important but not without risks.

    Sullivan RP, Ward L, Currie BJ

    International journal of infectious diseases : IJID : official publication of the International Society for Infectious Diseases 2019; (80()):111-114 doi:10.1016/j.ijid.2019.01.019.

    PMID: 30659921
  3. 3

    Antibiotic susceptibility of clinical Burkholderia pseudomallei isolates in northeast Thailand during 2015-2018 and the genomic characterization of β-lactam-resistant isolates.

    Fen SHY, Tandhavanant S, Phunpang R, et al.

    Antimicrobial agents and chemotherapy 2023; (95(5)) doi:10.1128/AAC.02230-20.

    PMID: 33593842
  4. 4

    Melioidosis in Critical Care: A Review.

    Sridharan S, Princess IB, Ramakrishnan N

    Indian journal of critical care medicine : peer-reviewed, official publication of Indian Society of Critical Care Medicine 2021; (25(Suppl 2)):S161-S165 doi:10.5005/jp-journals-10071-23837.

    PMID: 34345132
  5. 5

    Impact of nutritional stress on drug susceptibility and biofilm structures of Burkholderia pseudomallei and Burkholderia thailandensis grown in static and microfluidic systems.

    Anutrakunchai C, Bolscher JGM, Krom BP, et al.

    PloS one 2018; (13(3)):e0194946 doi:10.1371/journal.pone.0194946.

    PMID: 29579106
  6. 6

    Antimicrobial Susceptibility of Western Hemisphere Isolates of Burkholderia pseudomallei: Phenotypic and Genomic Analyses.

    Bugrysheva JV, Lascols C, McLaughlin HP, et al.

    Microbial drug resistance (Larchmont, N.Y.) 2021; (27(9)):1176-1185 doi:10.1089/mdr.2020.0362.

    PMID: 33570476
  7. 7

    Rare Neuromelioidosis Case that Required Long Intensive Phase Therapy.

    Ankala S, John T, Varghese B

    Oman medical journal 2025; (40(3)):e760 doi:10.5001/omj.2025.14.

    PMID: 41244001
  8. 8

    Craniospinal MRI Findings in Neuromelioidosis.

    Naik S, Bhoi SK, Jha M, Kumar M

    Neurology India 2023; (71(1)):113-118 doi:10.4103/0028-3886.370442.

    PMID: 36861583
  9. 9

    A Comparison Between 12 Versus 20 Weeks of Trimethoprim-sulfamethoxazole as Oral Eradication Treatment for Melioidosis: An Open-label, Pragmatic, Multicenter, Non-inferiority, Randomized Controlled Trial.

    Anunnatsiri S, Chaowagul W, Teparrukkul P, et al.

    Clinical infectious diseases : an official publication of the Infectious Diseases Society of America 2021; (73(11)):e3627-e3633 doi:10.1093/cid/ciaa1084.

    PMID: 32725199
  10. 10

    Burkholderia pseudomallei in Sarawak, Malaysian Borneo, Remains Highly Susceptible to Trimethoprim-Sulfamethoxazole Despite Resistance to Its Individual Components.

    Sumbu LL, Sia TL, Ooi MH, et al.

    Pathogens (Basel, Switzerland) 2026; (15(1)) doi:10.3390/pathogens15010110.

    PMID: 41599094
  11. 11

    Adverse reactions to trimethoprim/sulfamethoxazole for melioidosis eradication therapy: An evaluation of frequency and risk factors.

    Martin GE, Bramwell J, Gadil E, et al.

    International journal of infectious diseases : IJID : official publication of the International Society for Infectious Diseases 2025; (150()):107283 doi:10.1016/j.ijid.2024.107283.

    PMID: 39521392
  12. 12

    Melioidosis with a subdural collection - a case report.

    Amarasena HLP, Silva FHDS, Tilakaratna PMYI, et al.

    BMC infectious diseases 2019; (19(1)):143 doi:10.1186/s12879-019-3782-0.

    PMID: 30755178
  13. 13

    Drug-induced renal tubular acidosis in a patient receiving trimethoprim-sulfamethoxazole.

    Tan HL, Ee SCE, Zhao Y, Lew PS

    BMJ case reports 2025; (18(1)) doi:10.1136/bcr-2024-263500.

    PMID: 39875144
  14. 14

    The Risks of Using Trimethoprim/Sulfamethoxazole in Patients with Renal and Cardiac Compromise.

    Hoffman AF, Lin TL

    Journal of the American Podiatric Medical Association 2022; (112(5)).

    PMID: 36251600
  15. 15

    Trimethoprim-Sulfamethoxazole-Induced Pancytopenia: A Case Report.

    Chahal J, Junko G

    Cureus 2024; (16(12)):e75113 doi:10.7759/cureus.75113.

    PMID: 39759622
  16. 16

    Analysis of the Clinical Characteristics of Hyponatremia Induced by Trimethoprim/Sulfamethoxazole.

    Lei H, Liu X, Zeng J, et al.

    Pharmacology 2022; (107(7-8)):351-358 doi:10.1159/000523824.

    PMID: 35381593
  17. 17

    Disseminated Melioidosis from a Ruptured Infective Aortic Aneurysm and Pedal Ulcers to Septic Arthritis and Osteomyelitis: A Case Report.

    Jagan Sebastian J, Gnana Preethe B, Subramanian S

    Vascular specialist international 2025; (41()):20 doi:10.5758/vsi.250025.

    PMID: 40808240
  18. 18

    The Tunnel Sign Revisited: A Novel Observation of Cerebral Melioidosis Mimicking Sparganosis.

    Peh WM, Hean GG, Clement YHR

    Journal of radiology case reports 2018; (12(8)):1-11 doi:10.3941/jrcr.v12i8.3441.

    PMID: 30651915
  19. 19

    Tunnel sign on magnetic resonance imaging in neuromelioidosis: A systematic literature review.

    Gupta N, Singh S, Kumar TP, et al.

    New microbes and new infections 2025; (68()):101639 doi:10.1016/j.nmni.2025.101639.

    PMID: 41625698
  20. 20

    Development of neutropenic sepsis during the eradication phase with co-trimoxazole in patients with melioidosis: two case reports.

    Jayaweera JAAS, Ranasinghe G

    Germs 2023; (13(3)):266-272 doi:10.18683/germs.2023.1393.

    PMID: 38146382

This page explains melioidosis treatment protocols for educational purposes only. Always consult your infectious disease specialist or primary care provider regarding your specific antibiotic regimen, dosing, and side effect management.

Get notified when new evidence is published on Melioidosis.

We monitor PubMed for new peer-reviewed studies on this topic and email a short summary when something meaningful changes.